UroGen Pharma Ltd (URGN)
UroGen Pharma is a biotechnology company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co. has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Co.'s Jelmyto® (mitomycin) for pyelocalyceal solution, and its UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively.
URGN SEC Filing Email Alerts Service
Company Name: |
UroGen Pharma Ltd |
Website: |
www.urogen.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding URGN: |
16 |
Total Market Value Held by ETFs: |
$18.40M |
Total Market Capitalization: |
$518.00M |
% of Market Cap. Held by ETFs: |
3.55% |
|
|
March 29, 2024 1:54 AM Eastern
Strong Buy (3.60 out of 4)
62nd percentile
|
|